Organizer

ASK HEALTH ASIA

Strategic Partner

Singapore General Hospital
SingHealth

2026 Singapore–China Health and Life Sciences Innovation Summit

2026中新健康与生命科学创新峰会

Advancing Clinical Collaboration and Frontier Medical Technologies in the Asia-Pacific

携手推进亚太地区临床合作与前沿医疗科技发展

15 September 2026 • Singapore | 2026年9月15日 • 新加坡

Programme Book



Knowledge Partner

DukeNUS Medical School | Centre of Regulatory Excellence

Media Partner

Caixin GLOBAL

Time 时间	Program 议程	Speakers 嘉宾
08:00–09:00		**Registration 签到注册**
09:00–09:10	**Opening by the Summit Co-Moderators** **主持人开场**	**Moderator主持人:** **A/Prof LIM Boon Leng 林文龙** Clinical Director, Global Impact Office; Senior Consultant, Anaesthesiology, Singapore General Hospital 新加坡中央医院国际交流与合作办公室临床处长； 麻醉科高级顾问医生
		Moderator主持人: **Dr Chang LIU 刘畅** CEO & Founder, ASK Health Asia Adjunct Associate Professor, Chinese University of Hong Kong 艾社康亚洲创始人及CEO；香港中文大学兼职副教授
09:10–09:20	**Welcome Remarks** **欢迎致词**	**A/Prof TAN Hiang Khoon 陈向勤** Chief Executive Officer, Singapore General Hospital 新加坡中央医院行政总裁

Topic 1: Frontiers in Health and Life Sciences Innovation in Asia
议题1: 亚洲健康与生命科学前沿创新

Time 时间	Program 议程	Speakers 嘉宾
09:20–09:35	**Keynote Speech** **主旨演讲**	**Prof Sze Wee TAN** Advisor (Ecosystem Enablement – Healthcare & Life Sciences), Temasek Singapore; Advisor (Innovation & Enterprise), SingHealth 淡马锡新加坡顾问（生态系统赋能 – 医疗健康与生命科学）； 新加坡保健服务集团顾问（创新与企业发展）
09:35–09:50	**Keynote Speech** **主旨演讲**	**Dr Lei WU 吴蕾** Managing Director, SBP Group; Secretary-General, Biomedical Enterprises International Development Association (Shanghai) 中国生物制药创新药政总经理、 上海生物医药企业国际化发展协会秘书长
09:50–10:05	**Keynote Speech** **主旨演讲**	**Steven CHEN 陈洁宇** Business Development Director of International Business at United Imaging Healthcare 联影医疗国际业务业务拓展总监

Time 时间	Program 议程	Speakers 嘉宾
10:05–11:05	**Panel 1:** **Building the Architecture for Health and Life Sciences Innovation in Asia** **圆桌讨论一：** **构建亚洲健康与生命科学创新体系**	**Moderator主持人：** **A/Prof Jeremy LIM 林方源** CEO and Co-Founder AMILI, Associate Professor National University of Singapore Yong Loo Lin School of Medicine AMILI首席执行官兼联合创始人； 新加坡国立大学杨潞龄医学院副教授
		Cesar G CONCEPCION Chief Commercial Officer, Asia Pacific, Middle East & Africa, Novartis 诺华亚太、中东及非洲区首席商务官
		Prof William HWANG YK 黄殷祺 Senior Advisor, SingHealth; Co-Director, Regenerative Medicine Institute of Singapore (REMEDIS); Senior Consultant, Department of Haematology, National Cancer Centre Singapore and Singapore General Hospital 新加坡保健服务集团高级顾问； 新加坡再生医学研究院联合主任； 新加坡国立癌症中心及新加坡中央医院血液科高级顾问医生
		Margaret RUMPF Founder & CEO, Pearla Group Pte Ltd Pearla Group创始人兼首席执行官
		Dr Dongxu SHU 舒东旭 Co-Founder & CEO, Argo Biopharma 舶望制药联合创始人、首席执行官
		A/Prof Daniel TING 张书维 Director, AI Office, SingHealth; Chief Data and Digital Officer and Senior Consultant, Singapore National Eye Centre 新加坡保健服务集团人工智能办公室主任； 新加坡全国眼科中心首席数据与数字官兼高级顾问医师
		Geoff WANG 王铁峰 BD Director, Ascentage Pharma Group 亚盛医药业务拓展总监
11:05–11:20	**Photo Opportunity & Tea Break 合影及茶歇**	

Topic 2: Next-Generation Therapeutics and Translational Innovation in Asia
议题2：亚洲下一代创新疗法与转化创新

Time 时间	Program 议程	Speakers 嘉宾
11:20–11:35	**Keynote Speech** **主旨演讲**	**Adj Prof (Dr) Raymond CHUA 蔡瑞文** Chief Executive Officer, Health Sciences Authority (HSA), Singapore 新加坡卫生科学局局长
11:35–12:35	**Panel 2:** **Advancing Next-Generation Therapeutics in Asia** **圆桌讨论二：** **推动亚洲下一代创新疗法发展**	**Moderator主持人：** **Wai Chiew CHIK 植伟超** Managing Director, Healthcare & Pharmaceuticals/ Consumer Products, Institutional Banking Group, DBS Bank 星展银行企业及机构银行健康医疗行业组/消费品行业组董事总经理
		Dr Kevin CHOW 周家乐 Partner at Bayland Capital (the Corporate Venture Platform of Pharmaron) 康君资本合伙人（康龙化成企业风险投资平台）
		Dr Karen CHU 朱若蕾 Founder & CEO, Harvest Integrated Research Organization (HiRO) 贺维斯特医药创始人兼首席执行官
		Dr Yvonne KOH 许伊菱 Director (Biotech Investments), Clavystbio Clavystbio 总监（生物医药投资）
		A/Prof LIM Chwee Ming 林水明 Director, Clinical Translational Research; Head and Senior Consultant, Department of Otorhinolaryngology – Head & Neck Surgery, Singapore General Hospital 新加坡中央医院临床转化研究组长； 耳鼻喉头与颈外科主任兼高级顾问医生
		Prof Damian O' CONNELL 欧康明 CEO, Experimental Drug Development Centre (EDDC) hosted by A*STAR, Singapore 新加坡科技研究局实验药物研发中心CEO
		Dr Kim PNG-LIM 方家玲 Partner, Novo Holdings 诺和控股合伙人
12:35–13:40	**Lunch Break 午餐**	

Topic 3: AI-Enabled Diagnostics and Medical Technology Innovation
议题3：AI赋能诊断与医疗科技创新


Time 时间	Program 议程	Speakers 嘉宾
13:40–13:55	**Keynote Speech** **主旨演讲**	**Junjie ZHANG 张俊杰** Vice President of Ant Group, President of Ant Health Business Group 蚂蚁集团副总裁、蚂蚁健康事业群总裁
13:55–14:10	**Keynote Speech** **主旨演讲**	**Dr Xiaodong TAO 陶晓东** CEO, Xunfei Healthcare 讯飞医疗科技股份有限公司总裁
14:10–15:10	**Panel 3:** **AI in Driving Healthcare Transformation** **圆桌讨论三：** **AI驱动医疗转型**	**Moderator主持人:** **Asst Prof Kavitha PALANIAPPAN** Assistant Professor and Project Lead, Health Services Regulation, Centre of Regulatory Excellence (CoRE), Duke-NUS Medical School 杜克-新加坡国立大学医学院监管卓越中心助理教授兼卫生服务监管项目负责人
		A/Prof Adam CHEE Director, Artificial Intelligence Development Office, Singapore General Hospital 新加坡中央医院人工智能发展办公室主任
		Anne MA 马春娥 Founder & CEO, Shukun Technology 数坤科技创始人兼首席执行官
		Dr Shihao XU 徐诗皓 AI Research Scientist, Lyncia Lab, Tianqiao and Chrissy Chen Institute (TCCI) 天桥脑科学研究院灵溪Lab AI科学家
		Tianze ZHANG 张天泽 Founder & Chief Executive Officer, LinkDoc 零氪科技创始人兼首席执行官
		Dr Jiyun ZHENG 郑霁耘 Vice President & Board Secretary, Sinocare Inc. 三诺生物副总经理兼董事会秘书

Time 时间	Program 议程	Speakers 嘉宾
15:10–15:25	**Keynote Speech** **主旨演讲**	**Prof Chengli SONG 宋成利** Professor, School of Health Science and Engineering, University of Shanghai for Science and Technology 上海理工大学健康科学与工程学院教授
15:25–16:25	**Panel 4:** **Singapore–China Collaboration in Reshaping MedTech and Diagnostics** **圆桌讨论四：** **中新合作重塑医疗科技与诊断创新**	**Moderator主持人:** **Dr Eugene HONG 方祖仁** Head, Healthcare & Pharmaceutical, Institutional Banking Group, DBS Bank 星展银行机构银行集团医疗保健与制药主管
		Leni CHAN 陈炳良 Director, MedTech, Innovation & Enterprise, Agency for Science, Technology and Research (A*STAR) 新加坡科技研究局创新与企业部医疗科技总监
		Dr Robson EE 余汉健 Head of APAC, AmoyDx 艾德生物亚太销售总监
		Vijay KARWAL 伟绩加 Managing Director, CBC Group CBC Group董事总经理
		A/Prof Andrea KWA Lay Hoon 柯丽云 Deputy Director, Pharmacy (Research & Innovation), Singapore General Hospital; Associate Professor, Duke-NUS Medical School 新加坡中央医院药剂部研究与创新副处长; 杜克-新加坡国立大学医学院副教授
		A/Prof Joanne NGEOW 饶润仪 Associate Professor of Genomic Medicine, Lee Kong Chian School of Medicine, Nanyang Technological University; Head, Cancer Genetics Service, and Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore 南洋理工大学李光前医学院, 基因组医学副教授 新加坡国立癌症中心, 癌症基因咨询服务主任,肿瘤内科高级顾问
		Dr Kate QI 齐欢 Founder & CEO, SG Diagnostics SG Diagnostics创始人兼首席执行官
16:25–16:35	**Tea Break 茶歇**	

Topic 4: Translating Healthcare Innovation from Lab to Clinic
议题4：推动医疗创新从实验室走向临床

Time 时间	Program 议程	Speakers 嘉宾
16:35–16:50	**Keynote Speech** **主旨演讲**	**Dr Wei Yang CHEONG 张伟洋** Vice Provost for Strategic Research Partnerships at Singapore Management University; Senior Adviser for Health Economics at Singapore Ministry of Health; Board Oversight Committee Chair for Advanced Cell Therapy and Research Institute of Singapore (ACTRIS) 新加坡管理大学战略研究合作副教务长； 新加坡卫生部卫生经济学高级顾问； 新加坡细胞治疗与研究院监督主席
16:50–17:50	**Panel 5:** **Accelerating Patient Access to Innovation - From Bench to Bedside** **圆桌讨论五：** **从实验室到临床，加速患者获得创新成果**	**Moderator主持人：** **Ti-Hwei HOW 侯志辉** Founder & Principal Advisor, The Impact Catalyst SG; Senior Advisor of ASK Health Asia The Impact Catalyst SG 创始人兼首席顾问； ASK Health Asia高级顾问
		Zhiping CHEN 陈治平 CEO, Shengsheng International Logistics 生生国际总裁
		A/Prof Henry HO Sun Sien 何升全 Executive Director, National Health Innovation Centre Singapore (NHIC); Deputy Chief Executive Officer, Discovery & Future Health, Singapore General Hospital 新加坡国家医疗创新中心执行总监； 新加坡中央医院副行政总裁（探索与未来医疗）
		A/Prof Andrea LOW Hsiu Ling 刘秀玲 Research Director, Research Office; Senior Consultant, Department of Rheumatology & Immunology, Singapore General Hospital 新加坡中央医院研究处主任；风湿与免疫学高级顾问医生
		Dr Xiaoming PENG 彭晓明 CEO, Lion TCR 来恩生物首席执行官
		A/Prof Adrian TEO 赵奇强 Scientific Co-Founder, BetaLife Pte Ltd BetaLife 科学联合创始人
		Bowen WEI 魏博文 Associate Director, International Business Development and Strategy, Innogen 银诺医药国际业务拓展和战略副总监
17:50–18:00	**Closing Remarks: Strategic Collaboration Opportunities & Next Steps** **大会总结:合作机遇与未来方向**	

SPEAKER BIOGRAPHIES





A/Prof LIM Boon Leng 林文龙

Clinical Director, Global Impact Office; Senior Consultant, Anaesthesiology, Singapore General Hospital

新加坡中央医院国际交流与合作办公室临床处长; 麻醉科高级顾问医生

A/Prof Lim Boon Leng serves as Clinical Director of SGH's Global Impact Office and Director of Medical Affairs at SingHealth. He is a Senior Consultant in the Department of Anaesthesiology and holds academic appointments as Associate Professor at Duke-NUS Medical School and the Yong Loo Lin School of Medicine, National University of Singapore. He previously served as Chief Risk Officer at SGH. A/Prof Lim brings extensive leadership experience across clinical care, medical education, and healthcare governance. He previously served as Director, Surgical ICU, Head of the Department of Anaesthesia at SGH and was instrumental in establishing subspecialties including cardiac anaesthesia, neuroanaesthesia, liver transplant anaesthesia and Pain Medicine. His contributions to medical education include serving as Designated Institutional Official for SingHealth Residency and chairing national specialist Accreditation committee. He also chairs SGH Clinical Ethics Committee and Member of National Transplant Ethics Committee.



Dr Chang LIU 刘畅

CEO & Founder, ASK Health Asia
Adjunct Associate Professor, Chinese University of Hong Kong

艾社康亚洲创始人及CEO;香港中文大学兼职副教授

Dr. Chang LIU is the CEO and founder of ASK Health Asia. ASK Health Asia is a catalyst for health systems transformation in Asia. Through in-depth research, consultancy, platform creation, solution co-creation and resource connection, the company works closely with leading industry leaders to provide innovative solutions to jointly promote new tangible health policies and capture growth opportunities within a global emerging economy.Prior to establishing ASK Health Asia, Dr. Liu was a Regional Director at ACCESS Health International, Inc., a global non-profit organization, overseeing the business development in both China and Singapore for over seven years. As the work developed and matured across both regions, Dr. Liu formally spun off the ACCESS Health China entity into a ASK Health Asia, to fully accelerate the company’s work and impact across Asia.Dr. Liu holds a Master's degree in Finance from Guanghua School of Management of Peking University (2009) and a Ph.D. from Brown University in Health Economics (2013). Thereafter, he was a research assistant Professor at the Duke NUS Graduate School of Medicine. Dr. Liu authored publications, including the afterword of Affordable Excellence, a book that documents the evolution of Singapore's healthcare system towards quality and sustainability between 2013 and 2014, as well as coauthored A City for All Ages, which documents the current state and development of the ageing industry in Singapore, with Dr. William Haseltine, the Chairman and Founder of ACCESS Health International, Inc.



A/Prof TAN Hiang Khoon 陈向勤

Chief Executive Officer, Singapore General Hospital

新加坡中央医院行政总裁

A/Prof Tan Hiang Khoon serves as Chief Executive Officer of Singapore General Hospital and Senior Consultant at the SingHealth Duke-NUS Head & Neck Disease Centre. He previously led international collaboration efforts as Group Director at SingHealth and Director of the SingHealth Duke-NUS Global Health Institute. During COVID-19, he provided national leadership in managing Singapore's largest community care facility. Professor Tan holds medical and Executive MBA degrees from the National University of Singapore, a PhD from the University of Bristol, and completed advanced surgical training in France.



Prof Sze Wee TAN

Advisor (Ecosystem Enablement – Healthcare & Life Sciences), Temasek Singapore;
Advisor (Innovation & Enterprise), SingHealth

淡马锡新加坡顾问(生态系统赋能 – 医疗健康与生命科学);
新加坡保健服务集团顾问(创新与企业发展)

Education and Training : Professor Tan graduated with MBBS from National University of Singapore (NUS), and attained his MBA from Warwick University, UK. He attended the Stanford Executive Programme at the Stanford University' s Graduate School Business, and was awarded a certificate of completion for the Senior Fellowship in Public Service Programme, Lee Kuan Yew School of Public Policy in Singapore. Prof Tan also attended the Executive Leadership Programme from the Singapore Civil Service College. He is an affiliate member of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, UK. He is a registered medical practitioner with the Singapore Medical Council.

Leadership Appontment : Prof Tan Sze Wee, is currently Advisor to Temasek Singapore Pte Ltd. Temasek is a global investment company headquartered in Singapore with a multinational staff of over 900 people. Prof Tan will be supporting Temasek at BioSparc in Suzhou. This is a China-Singapore Life Sciences Park, which Temasek is working on with Suzhou Industrial Park. It aims to build on the SIP' s strengths in the biomedical sector, providing research and development centres and manufacturing facilities to advance cutting-edge innovations from drug development and medical devices to artificial intelligence-driven medical technologies.

Between 2009 to 2025, Prof Tan served various leadership roles in the Agency for Science, Technology and Research (A*STAR), which is Singapore's lead public sector R&D agency. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with over 6,000 staff within 17 research entities and national platforms primarily located in Biopolis and Fusionopolis.

Prof Tan' s career in A*STAR started in 2009. He was first appointed as Programme Director of the A*STAR Medical Technology initiative in Science and Engineering Research Council (SERC), that led in the partnership with Stanford BioDesign @ Stanford University, and Center for Integration of Medicine & Innovative Technology (CIMIT) in Massachusetts General Hospital in Boston, USA. Prof Tan was subsequently appointed as Director (SERC), where he oversaw all SERC cluster-led research and development (R&D). From 2012 to 2015, Prof Tan was Deputy Executive Director (DED), Biomedical Research Council (BMRC) and his cross-Council experience enabled A*STAR to engage companies across industry sectors.

In 2016, Prof Tan was appointed ED, SERC and was subsequently redesignated as Assistant Chief Executive (ACE), SERC in 2019. As ACE SERC, Prof Tan drove the implementation of strategic plans and initiatives set for A*STAR in the Science and Engineering areas. Prof Tan was appointed ACE, Innovation and Enterprise as well as Acting Chief Executive of A*ccelerate Technologies Pte Ltd in 2020. He aligned A*STAR industry engagement, licensing and venture creation value chain among the A*STAR Research Institutes and the National Platforms. This is to drive efforts to translate A*STAR' s R&D to market so as to enable research-fuelled economic and societal impact.

From 2023 to 2025, Prof Tan was appointed ACE BMRC. BMRC supports, oversees and coordinates public sector biomedical research and development activities in Singapore to cultivate a thriving biomedical cluster. At BMRC, he oversaw the development of core research capabilities in bioprocessing, genomics and proteomics, molecular and cell biology, bioengineering and nanotechnology, and computational biology. Prof Tan also served on the governance committee of National Platforms Diagnostic Development Hub (DxDHub), Experimental Drug Development Centre (EDDC) and Medtech Catapult.

Prior to these roles, Prof Tan was the Managing Director and Chief Executive Officer of Rockeby biomed Limited from 2001 to 2009. He was the Asia-Pacific Associate Regional Medical Director for Mead Johnson Nutritional' s, a division pf Bristol-Myers Squibb Company from 1997 to 2001.

Academic, Clinical and Innovation Focus : Professor Tan constantly promotes international research, innovation and enterprise partnership between Singapore, A*Star and its key scientific, industry and venture building partners across the world. He has forged bilateral research partnership programmes between Singapore and China, Germany, Korea, Japan, New Zealand. He is a speaker at international conferences on topics around medical technologies, AI in Healthtech, and advises academic, corporate and not for profit organisations for wide range of topics. Within A*STAR, he oversees close to 2,000 research scientists and engineers during his stint at BMRC and SERC, each with annual operating budget of US$300M.

Professional Service: Professor Tan has served on various national committees in Singapore. He is a member of the Board Oversight Committee for Advanced Cell Therapy and Research Institute, Singapore (ACTRIS). He is a board member of the Singapore Eye Research Institute (SERI) as well as a member of its Incubator Advisory Board for the SERI Ophthalmic Technologies Incubator Phase II Program. He is a council member of the Singapore Medical Association (SMA), as well as a board director for SMA Pte Ltd. Prof Tan is also the Chairman of Unlocking ADHD Ltd.

Awards & Honours : Professor Tan was a former Nominated Member of Parliament of Singapore, and is a recipient of the Singapore Public Administration Medal (Silver) as well as the Singapore (Covid-19) Public Administration Medal (Silver). He has also received the Friend of Labour Award.



Dr Lei WU 吴蕾

Managing Director, SBP Group; Secretary-General, Biomedical Enterprises International Development Association (Shanghai)

中国生物制药创新药政总经理、上海生物医药企业国际化发展协会秘书长

Linda Wu has worked for MNCs, a local leading pharmaceutical company, and RDPAC over her nearly 25-year career. She is responsible for external collaborations and the submission and approval of innovative products across multiple therapeutic areas, with a focus on optimizing global development and regulatory strategies and ensuring their effective execution.

She serves as a member of the Professional Committee on Drug Development Regulation under the China Association for Drug Supervision and Management, a member of the DIA Regulatory Science Committee, and a special researcher at Yeehong Business School (a pharmaceutical industry-focused institution affiliated with Shenyang Pharmaceutical University). She is committed to improving the innovation ecosystem and pharmaceutical policy environment in China, the Asia-Pacific region, and Belt and Road Initiative countries, with the ultimate goal of enhancing patient access to innovative medicines.

She holds a Ph.D. in Management from the joint program of University of Nice and Shanghai Jiao Tong University, an EMBA from The Chinese University of Hong Kong, and a B.S. in Pharmaceutical Analysis from China Pharmaceutical University.



Steven CHEN 陈洁宇

Business Development Director of International Business at United Imaging Healthcare

联影医疗国际业务业务拓展总监

Steven Chen is the Business Development Director at United Imaging Healthcare (UIH), overseeing international business development and strategic key accounts. In this role, he drives strategic partnerships and cross-border collaborations with leading healthcare institutions and global industry partners.

Steven brings extensive experience across medical devices, pharmaceuticals, consulting, and assurance, with expertise spanning corporate strategy, business development, commercial leadership, and strategic partnerships. Prior to joining UIH, he held key commercial and management roles at Boehringer Ingelheim, Johnson & Johnson Medical Devices, and Deloitte.

He holds an MBA from the USC Marshall School of Business and a Bachelor’ s degree in Economics from Shanghai University of Finance and Economics.



A/Prof Jeremy LIM 林方源

CEO and Co Founder AMILI; Associate Professor National University of Singapore Yong Loo Lin School of Medicine

AMILI首席执行官兼联合创始人；新加坡国立大学杨潞龄医学院副教授

A/Prof Jeremy Lim is CEO and Co Founder of AMILI, a Singapore based precision health startup centered on the gut microbiome and serving Southeast Asia. He trained in surgery, public health and lifestyle medicine. Outside of AMILI, he holds faculty roles in NUS Medicine and Monash University and maintains an active academic advisory practice in healthcare financing.



Cesar G CONCEPCION

Chief Commercial Officer, Asia Pacific, Middle East & Africa, Novartis

诺华亚太、中东及非洲区首席商务官

Cesar Concepcion has served as Chief Commercial Officer, Asia Pacific, Middle East and Africa (APMA) since April 2022. With over 30 years of pharmaceutical industry experience, he joined Novartis in 2005 after holding senior marketing and general management roles across Asia Pacific. He has led successful business transformations in US, Latin America, China, Spain, Central Eastern Europe (CEE), and APMA, consistently driving growth, accelerating access to medicines, and delivering major product launches. Notable achievements include turning Novartis Oncology China into a top global business, transforming Spain' s commercial model towards specialty care, and elevating CEE to a $1bn business. Cesar is recognised for building high-performing teams and fostering a culture of excellence, innovation, and people development.



Prof William HWANG YK 黄殷祺

Senior Advisor, SingHealth; Co-Director, Regenerative Medicine Institute of Singapore (REMEDIS); Senior Consultant, Department of Haematology, National Cancer Centre Singapore and Singapore General Hospital

新加坡保健服务集团高级顾问;新加坡再生医学研究院联合主任;
新加坡国立癌症中心及新加坡中央医院血液科高级顾问医生

Prof William Hwang YK is a haemato-oncologist with over 25 years of experience in stem cell transplantation and cell therapy. He currently serves as Senior Consultant, Department of Haematology, Singapore General Hospital and National Cancer Centre Singapore; Co-Director, Regenerative Medicine Institute of Singapore (REMEDIS); and Senior Advisor, SingHealth. A recipient of the 2023 National Outstanding Clinician Award, he holds key national leadership roles in cancer and cell therapy. Formerly CEO of NCCS (2017 – 2023), he is internationally recognised in haematology and transplantation, has held leadership positions in major global organisations, and authored over 150 scientific publications and several books.



Margaret RUMPF

Founder & CEO, Pearla Group Pte Ltd

Pearla Group创始人兼首席执行官

Margaret is the founder and CEO of Pearla Group, a Singapore based company that strategically advises investors and executive teams looking to maximise asset value and accelerate market adoption. With a deep understanding of commercialization pathways and investment landscapes, she helps organisations navigate complex regulatory environments, optimize market entry, and drive scalable growth. Known for bridging the gap between clinical innovation and commercial success, Margaret also serves on A*STAR Singapore Therapeutics Development Review (STDR) Expert Review Panel and regularly instructs at the National Graduate Research and Innovation Program. Prior to this, Margaret held global senior executive positions with accountability to run complex global P&L businesses in pharmaceutical and vaccines at GSK.



Dr Dongxu SHU 舒东旭

Co-Founder & CEO, Argo Biopharma

舶望制药联合创始人、首席执行官

Dr. Dongxu Shu is the Founder, CEO of Argo Biopharma, a leading China-based siRNA biotechnology company with growing global recognition. He has led the development of Argo' s innovative RNA therapeutics platform and pipeline, which now comprises more than 40 products, including eight clinical-stage assets. Argo has entered into several landmark licensing and collaboration agreements with Novartis, with a combined transaction value exceeding US$13 billion.

Prior to founding Argo, Dr. Shu worked at Arrowhead Pharmaceuticals, a publicly listed global biotechnology company specializing in siRNA therapeutics. Dr. Shu holds degrees in Organic Chemistry from the University of Peking University and the University of Wisconsin-Madison and completed his postdoctoral research at Northwestern University.



A/Prof Daniel TING 张书维

Director, AI Office, SingHealth; Chief Data and Digital Officer and Senior Consultant, Singapore National Eye Centre

新加坡保健服务集团人工智能办公室主任；
新加坡全国眼科中心首席数据与数字官兼高级顾问医师

A/Prof Daniel Ting, MD, PhD, is a Duke-NUS and Stanford professor, internationally recognised surgeon-scientist, AI researcher, and technology entrepreneur advancing healthcare transformation. He is Founding Co-Director of the SingHealth Duke-NUS Artificial Intelligence in Medicine Institute, a member of Singapore' s Ministry of Health AI Steering Committee, and a core leader of SIMFONI, Singapore' s national healthcare foundation-model programme. His work spans multimodal, generative, and agentic AI, responsible governance, and real-world clinical deployment. Named among Stanford University' s World' s Top 2% Scientists from 2022-2026, he has authored over 400 peer-reviewed publications. He develops trusted, sovereign AI systems that safely transform healthcare discovery, delivery, operations, and scale.



Geoff Wang 王铁峰

BD Director, Ascentage Pharma Group

亚盛医药业务拓展总监

Geoff Wang, he has worked more than thirty years in multiple background multi-national companies, which include MSD, UCB, Daiichi-Sankyo, etc. In Business Development, he has worked more than seventeen years including thirteen years in Takeda. He completed many different types of transactions, for example in-license, out-license, divestment, M&A, co-commercialization, and alliance management post signing agreements. Those transactions covered therapeutic areas such as GI, Oncology, Neuroscience, Gene therapy, Cardiovascular & Diabetes, Plasma products.



Adj Prof (Dr) Raymond CHUA 蔡瑞文

Chief Executive Officer, Health Sciences Authority (HSA), Singapore

新加坡卫生科学局局长

Raymond Chua Swee Boon is a public health trained physician and presently the Deputy Director-General of Health (Health Regulation) at Singapore' s Ministry of Health (MoH) and the Chief Executive Officer of the Health Sciences Authority (HSA), overseeing the regulations of healthcare services, information and health products respectively. He is currently leading a regulatory transformation review to synergize regulatory operations across healthcare services, information, and products. With over 25 years of experience in both public healthcare and the private pharmaceutical sector, he has driven transformative regulatory initiatives, including the enactment of the Human Biomedical Research Act and the Healthcare Services Act, which modernized Singapore' s healthcare regulatory framework. He pioneered regulatory sandboxes for innovations such as telemedicine, mobile inpatient care-at-home, and clinical genomic services, and introduced governance measures for emerging technologies like precision medicine and AI. During the COVID-19 pandemic, he served as Deputy Commander of the Medical Operations Taskforce, playing a key role in clinical operations, testing infrastructure, and enforcement of control orders. Raymond holds adjunct positions at the NUS Saw Swee Hock School of Public Health and Duke-NUS Centre of Regulatory Excellence, and academic credentials including a Bachelor of Medicine and Surgery from NUS, an MSc in Public Health from the London School of Hygiene and Tropical Medicine, and an MBA from the University of Nottingham.



Wai Chiew CHIK 植伟超

Managing Director, Healthcare & Pharmaceuticals/Consumer Products, Institutional Banking Group, DBS Bank

星展银行企业及机构银行健康医疗行业组/消费品行业组董事总经理

Wai Chiew is currently MD, Healthcare & Pharmaceutics / Consumer Products at DBS Bank. He has 30 years of experience in global investment management and strategic business development, with a strong track record of building and transforming businesses across healthcare, education, agri-food, technology, and sustainability sectors. Most recently, he was CEO & Executive Director at Heritas Capital, where he led the growth of a MAS-licensed fund management platform and significantly expanded its assets-under-management by launching multiple VC/ PE/ Fof / impact funds to back fast-growing deep-tech and impactful ventures throughout Asia. Prior to that, he held various senior roles at Singapore EDB and A*STAR, and served as Chief Representative and GM at Temasek' s Shanghai office. Within the healthcare space, he has led investments into hospitals and clinics, digital health, medtech and biotech, as well as LP commitments into healthcare-focused funds deploying into India, China, Southeast Asia, Europe and US on behalf of corporate and family office investors. He has also served on various listed and private companies' boards to advance sustainable growth and sound governance, as a Senior Accredited Director with the Singapore Institute of Directors. Wai Chiew has a BA (Economics) from Cambridge University (UK); MA from Yale University (USA) and EMBA from Cheung Kong Graduate School of Business (China).



Dr Kevin CHOW 周家乐

Partner at Bayland Capital (the Corporate Venture Platform of Pharmaron)

康君资本合伙人(康龙化成企业风险投资平台)

Dr. Kevin Chow is a Partner at Bayland Capital, the exclusive venture investment platform of Pharmaron (SZSE: 300759 / HKEX: 3759). He focuses on frontier technologies and artificial intelligence, particularly their applications in life sciences and healthcare. Kevin has extensive experience in venture capital, private equity, mergers and acquisitions, and capital markets, having led domestic and cross-border transactions worth over US$2.8 billion. Previously, he held senior positions at HG Capital, SF Holding, Li & Fung Group, and China Renaissance. He holds a jointly conferred DSc from Tsinghua University PBC School of Finance and Temple University, an LLB from the University of Hong Kong, and is qualified as a solicitor in Hong Kong.



Dr Karen CHU 朱若蕾

Founder & CEO, Harvest Integrated Research Organization (HiRO)

贺维斯特医药创始人兼首席执行官

Nearly 20 years of international CRO industry management and operational experience, with extensive leadership experience across both Eastern and Western markets. Served as Head of Clinical Operations at leading international CROs.



Dr Yvonne KOH 许伊菱

Director (Biotech Investments), Clavystbio

Clavystbio 总监（生物医药投资）

Yvonne brings a unique blend of commercial and public sector experience to investing and venture building. Her multi-faceted career includes roles in venture capital investing, business strategy, product development, technology commercialization, and innovation policy across the biotech and medtech sectors.

Yvonne was previously at Lightstone Ventures (LSV) and was involved in due diligence and program management for the firm' s early-stage ventures globally and in Singapore. Prior to that, Yvonne was Deputy Director at the National Research Foundation where she led the development and implementation of Singapore' s innovation strategy. She has also held operational roles at a Singapore-based medical diagnostics start-up.
Yvonne holds a PhD in Biochemistry from the University of Wisconsin Madison, USA, and BSc in Molecular Biology from the University of Illinois Urbana-Champaign, USA.



A/Prof LIM Chwee Ming 林水明

Director, Clinical Translational Research; Head and Senior Consultant, Department of Otorhinolaryngology – Head & Neck Surgery, Singapore General Hospital

新加坡中央医院临床转化研究组长；耳鼻喉头与颈外科主任兼高级顾问医生

A/Prof Lim Chwee Ming serves as Head and Senior Consultant of Otorhinolaryngology - Head & Neck Surgery at Singapore General Hospital and Senior Consultant at the SingHealth Duke-NUS Head and Neck Centre. He obtained his MBBS and Master of Medicine (Otorhinolaryngology) from the National University of Singapore in 1998 and 2006 respectively, and is a Member of the Royal College of Surgeons of Edinburgh. He completed a two-year Head and Neck Oncologic Fellowship at the University of Pittsburgh Medical Center, USA from 2010 to 2012. A/Prof Lim is an established clinician scientist who serves as Director of Clinical Translational Research at SGH, Co-Lead of Cancer Research Peak, and Academic Deputy Vice Chair of Research for the Surgery Academic Clinical Programme. His significant contributions to research have been recognised with the Outstanding Researcher Award at the 2022 GCEO Excellence Awards and the Silver Award at the 2024 Singapore Health Quality Service Awards.



Prof Damian O' CONNELL 欧康明

CEO, Experimental Drug Development Centre (EDDC) hosted by A*STAR, Singapore

新加坡科技研究局实验药物研发中心CEO

Prof. Damian O'Connell is CEO of Singapore's Experimental Drug Development Centre (EDDC), the national drug discovery and development platform under A*STAR. A physician-scientist with over 20 years of leadership across academia and global biopharma, he previously held senior R&D roles at Bayer Pharma, Pfizer, Parke Davis, Elan Pharmaceuticals, and Neurex, leading teams in clinical sciences, translational medicine, and drug safety. He has held faculty positions at the University of Virginia and University College Cork, where he remains Adjunct Professor of Medicine. He earned his M.D. and Ph.D. from the National University of Ireland and is a Fellow of several professional societies.



Dr Kim PNG-LIM 方家玲

Partner, Novo Holdings

诺和控股合伙人

Kim Png is a Partner at Novo Holdings, based in Singapore, where she focuses on biotech venture investments, with an emphasis on novel biology platforms and cross-border opportunities across Asia-Pacific.

Prior to joining Novo Holdings, Kim was with Polaris Partners, where she established the firm's Singapore office and managed a portfolio of biotech companies across the US, Europe, and Singapore. She was previously with Temasek's Life Sciences Investment Group, where she invested across private and public biotechnology companies globally and played a founding role in ClavystBio, Temasek's life sciences investment and venture-building platform.

Kim holds a PhD in Biomedical Sciences from Rockefeller University, a Master of Business Administration from Singapore Management University, and a BSE in Biomedical Engineering from Duke University.



Junjie ZHANG 张俊杰

Vice President of Ant Group, President of Ant Health Business Group

蚂蚁集团副总裁、蚂蚁健康事业群总裁

Mr. Junjie Zhang currently serves as Vice President of Ant Group and President of Ant Health Business Group. Since joining Ant Group in 2014, he has focused on healthcare insurance payments, hospital digitalization, and AI-driven healthcare solutions, committed to leveraging technological innovation to advance the inclusive development of healthcare services.

Under his leadership, Ant Health has evolved into a platform connecting hundreds of millions of users with professional medical resources. His efforts in developing Ant’ s Afu application as well as its medical large language model have led to widespread industry recognition.

Mr. Zhang also holds positions as a Standing Committee Member of both the Payment Reform Committee and the Information Technology and Big Data Committee under the China Health Insurance Research Association.



Dr Xiaodong TAO 陶晓东

CEO, Xunfei Healthcare

讯飞医疗科技股份有限公司总裁

Xiaodong Tao, graduated from University of Science and Technology of China with a B.S. degree in Electrical Engineering. In 2005, he obtained his Ph.D. degree in Electrical and Computer Engineering from the Johns Hopkins University. Since then, he worked in General Electric Company and Royal Philips Electronics of the Netherlands, where he led teams working on research and development of cutting-edge technologies for healthcare and medical equipment, in particular, imaging devices, imaging methods, clinical applications, and radiology solutions. Dr. Tao joined iFLYTEK Health in Jan. 2017 as the CEO. In 2021, The University of Science and Technology of China hired him as the doctoral tutor of biomedical engineering.



Asst Prof Kavitha PALANIAPPAN

Assistant Professor and Project Lead, Health Services Regulation, Centre of Regulatory Excellence (CoRE), Duke-NUS Medical School

杜克-新加坡国立大学医学院监管卓越中心助理教授兼卫生服务监管项目负责人

Dr. Kavitha Palaniappan is an Assistant Professor and Project Lead for Health Services Regulation at the Centre of Regulatory Excellence (CoRE), Duke-NUS Medical School, Singapore. She is an internationally recognised researcher in regulatory science, healthcare AI and digital health governance, leading multidisciplinary research that informs the regulation of emerging health technologies and supports evidence-based health policy. Her work spans AI governance, healthcare services regulation, digital health, regulatory preparedness, medical devices, longevity technologies and regulatory innovation, with a strong emphasis on translating research into practical policy and regulatory frameworks.

Working in close partnership with Singapore's Ministry of Health (MOH), Health Sciences Authority (HSA) and international regulatory organisations, Dr. Palaniappan leads major research programmes on AI-enabled health technologies, horizon scanning, regulatory preparedness and health systems innovation. She has also designed and delivered executive education and capacity-building programmes for regulators and policymakers across Asia, Europe and Africa.

Dr. Palaniappan has authored numerous peer-reviewed publications in regulatory science, digital health, occupational and environmental health, and healthcare policy, and is an invited speaker at international conferences on AI governance, digital health regulation and regulatory innovation. She is also a Conjoint Associate Professor at the University of Newcastle, Australia.



A/Prof Adam CHEE

Director, Artificial Intelligence Development Office, Singapore General Hospital

新加坡中央医院人工智能发展办公室主任

A/Prof Adam Chee is a digital health and health informatics leader, currently serving as Director of the AI Development Office (AIDO) at Singapore General Hospital. He brings deep expertise across healthcare, technology, innovation, and business transformation, with experience spanning clinical information systems, strategic consulting, standards development, AI-enabled health, and health systems transformation. Adam has worked across Asia Pacific and the Middle East, supporting the adoption of evidence-based, technology-enabled healthcare solutions. He also serves in multiple regional and international leadership roles, including HL7 Singapore, HL7 Asia, ISO TC215, WHO, APEC, and universities in the region.
Further details: www.GoBeyondNoise.com



Anne MA 马春娥

Founder and CEO of Shukun Technology

数坤科技创始人兼首席执行官

Ms. Ma is a distinguished entrepreneur in the information technology industry with profound expertise in technology R&D and corporate governance. She earned her bachelor' s degree from Northwestern Polytechnical University and a master' s degree in Applied Finance from Tsinghua University, and is a Yale Sinovation Fellow at Yale School of Management. Earlier in her career, she worked as a researcher at the IBM Emerging Technology Institute, where her outstanding professional accomplishments earned her the "Best of IBM" Award and the IBM Outstanding Technical Contribution Award.

In 2017, Ms. Ma founded Shukun Technology and has served as its Chief Executive Officer ever since. Leveraging her robust technical research expertise and sophisticated management insights, she has led the company to emerge as a global pioneer in medical artificial intelligence. Shukun Technology has independently developed domain-specific healthcare multimodal large models and proprietary AI Agentic Doctor solutions, which are widely deployed in smart city healthcare systems, hospital scenarios, home healthcare and other key sectors, securing the broadest market coverage across the industry.



Dr Shihao XU 徐诗皓

AI Research Scientist, Lyncia Lab, Tianqiao and Chrissy Chen Institute (TCCI)

天桥脑科学研究院灵溪Lab AI科学家

Dr. Xu Shihao is an AI Research Scientist at the TCCI Research Center and Shanda' s Lyncia Lab. His work focuses on the development and clinical translation of artificial intelligence technologies for mental health. He received his Ph.D. from the School of Electrical and Electronic Engineering at Nanyang Technological University (NTU), Singapore. His research centers on multimodal AI systems that analyze human behavior and mental states through speech, language, facial expressions, and body movements captured in audiovisual recordings. He was working as a Senior Algorithm Engineer at Huawei' s 2012 Laboratories, conducting research on multimodal search, recommender systems, and multimodal large language models. His research on schizophrenia and depression has been published in npj Schizophrenia and npj Mental Health Research. His broader AI research has appeared at leading conferences and journals, including KDD, EMNLP, ACM Multimedia, EMBC, TCSVT, etc. He has also served as a Workshop Chair for the ACM Multimedia Conference.



Tianze ZHANG 张天泽

Founder & Chief Executive Officer, LinkDoc

零氪科技创始人兼首席执行官

Mr. Tianze Zhang is the founder and CEO of LinkDoc. He graduated from Beijing University of Posts and Telecommunications with bachelor' s degree of Computer Science, and got EMBA degree from the China Europe International Business School. Currently, he serves as the Intelligence Medical Secretary-general and Vice Chairman of the Chinese Society of Clinical Oncology (CSCO), the first executive Intelligence Medical Professional Committee member of Chinese Medical Doctor Association, Member of the Yabuli Youth Forum, Representative of the People's Congress of Tianjin Binhai New Area, Chairman of the Digital Healthcare Committee of the China Europe Alumni Healthcare Industry Association (CAHA).

Mr. Zhang Tianze has served as the Product Manager of Tencent and the Product Operations Manager of Alibaba, accumulating extensive work experience in leading internet enterprises, and forming a data-based product thinking and operation path. Mr. Zhang has served as the CEO of Trustone Technology and Trustone Digital Media Company, serving well-known enterprises and large medical institutions. Within three years, he joined the ranks of digital communication and brand building frontline media. Mr. Zhang established LinkDoc Technology in 2014, dedicated to building a local medical big data platform and medical artificial intelligence solutions in China. LinkDoc Technology was listed on the 2023 Hurun Unicorn rankings.



Dr Jiyun ZHENG 郑霁耘

Vice President & Board Secretary, Sinocare Inc.

三诺生物副总经理兼董事会秘书

Dr. Jiyun Zheng serves as Vice President and Board Secretary of Sinocare Inc., Asia's largest solution provider of diabetes management. She oversees corporate governance, legal affairs, investment portfolios, and investor relations, while also driving global strategic partnerships. Her academic foundation encompasses undergraduate studies, doctoral training, and postdoctoral research in biomedical science and engineering at the National University of Singapore and A*STAR. Currently, she is championing the integration of artificial intelligence with biosensing technologies, seeking to translate CGM data into actionable insights for personalized diabetes management and to accelerate the digital transformation of chronic care delivery.



Prof Chengli SONG 宋成利

Professor, School of Health Science and Engineering, University of Shanghai for Science and Technology

上海理工大学健康科学与工程学院教授

Professor Song is the Executive Director of Shanghai Institute for Minimally Invasive Therapy (SIMIT), School of Health Science and Engineering at the University of Shanghai for Science and Technology (USST). He has a PhD in Mechanical Engineering from Cardiff University, UK and a Master in Biomedical Engineering from Southeast University, Nanjing China.

Professor Song' s research interest includes minimally invasive devices, smart materials and biomechanics. He has invented a number of medical devices which have been approved by China FDA and CE mark. His research has won a number of national and international awards, including Shanghai Science and Technology Award. He has published more than 200 papers and 50 patents, he translated Stanford Biodesign Chinese Edition.
He is the Chairman of Shanghai HiMed Medical Device Incubator, which has more than 50 spin-off companies in medical devices, and among them 8 CEOs from Prof. Song' s lab.



Dr Eugene HONG 方祖仁

Head, Healthcare & Pharmaceutical, Institutional Banking Group, DBS Bank

星展银行机构银行集团医疗保健与制药主管

Dr Eugene Hong joined DBS in 2016 and is currently Executive Director of Institutional BankingGroup heading the Global Healthcare sector within DBs Bank. He has more than 20 years of experience that spans across the healthcare value chain, he had taken up senior leadership positionsat corporations such as Parkway, GE Healthcare, Novartis and National Australia Bank. His currentrole at DBs involves developing integrated financial services solutions for the healthcare industryincluding the milestone capital market activities in the SGx and IDX. He is also leading a sustain-able healthcare ecosystem drive especially with regards to healthcare payments. His currentportfolio of clients includes major healthcare players within Asia as well as western multi-nationalcorporates. He graduated from Monash University in Master Health Service Management & MBBsMedicine and has also obtained a Master of Science, Global Finance from New York University.



Leni CHAN 陈炳良

Director, MedTech, Innovation & Enterprise, Agency for Science, Technology and Research (A*STAR)

新加坡科技研究局创新与企业部医疗科技总监

Leni is an accomplished professional with over 17 years of experience in the Medtech industry. Starting his journey at Singapore's largest tech transfer office, Leni was entrusted with the vital responsibility of commercializing an extensive portfolio of medical technology products, which included diagnostic software, surgical intervention tools, and devices for clinical and wellness applications. Over the course of his career, Leni has demonstrated acumen in various areas, including business development, product management, and strategic M&A. Currently, Leni is once again with A*STAR, where he leads Technology-Business Development for the MedTech Sector and is focused on delivering impactful outcomes.



Dr Robson EE 余汉健

Head of APAC, AmoyDx

艾德生物亚太销售总监

Dr. Robson is a global diagnostics leader with over a decade of experience accelerating equitable patient access to precision oncology across the Asia-Pacific. As Head of APAC, he led the historic, first-ever multi-gene PCR reimbursement for NSCLC in Japan—a program now covering 23 CDx testing ~35,000 patients annually. He has also established AmoyDx' s international headquarters in Singapore, leveraging its 80% China market share to drive regional expansion. Under his leadership, AmoyDx achieved market dominance across APAC, including a 99% ROS1 share in Korea, 50% NSCLC share in Japan, and 40% NSCLC share in Taiwan.



Vijay KARWAL 伟绩加

Managing Director, CBC Group

CBC Group 董事总经理

Vijay Karwal is a Managing Director of CBC Group, based in Singapore. In his role, he advises on sourcing and execution of investment opportunities as well as portfolio management, leading regional Southeast Asia coverage for the firm, together with providing global origination support for CBC' s royalty & credit strategy RBF funds. Vijay was previously an Operating Partner of CBC in which capacity he served as Executive Director and CEO of AffaMed Therapeutics, a Shanghai headquartered CBC portfolio company developing innovative solutions for ophthalmic disorders, which he first joined as CFO. He contributes over 25 years of global management and advisory experience in the healthcare industry with extensive background in strategy, business development, M&A and capital raising gained in roles in industry and as a senior investment banker. He currently serves as a Director of CBC portfolio companies Dawn Medical Technologies, AffaMed Therapeutics and Motiva China, as well as CBC' s healthcare infrastructure (HIP) real estate fund management platform, and is also an Independent Director of Mega Lifesciences PCL, one of the largest pharmaceutical groups in Southeast Asia, stock exchange listed and headquartered in Thailand, and OneSource Specialty Pharma Ltd, a leading global biologics and specialty pharma CDMO, stock exchange listed and headquartered in India.

Vijay joined CBC from Nomura International in Hong Kong, where he served as Managing Director and Head of Healthcare Investment Banking for the Asia (ex-Japan) region. Prior to Nomura, he was Chief Development Officer, Asia Pacific, as well as General Manager of China operations for DaVita Inc., the NYSE-listed global

provider of kidney care services. Vijay previously held several senior investment banking roles globally, including as Co-Head of M&A at CIMB Investment Bank, Asia Pacific Head of Consumer, Retail & Healthcare coverage at RBS, Head of Healthcare Banking in North America at ABN AMRO and RBS, and as a senior member of ABN AMRO Rothschild - the global equity capital markets joint venture between the Rothschild and ABN AMRO groups. Throughout his career he has been involved in a wide variety of advisory and financing transactions in the healthcare sector representing over $95 billion in transaction value, gaining extensive global experience across postings in London, Chicago, New York, Hong Kong and Singapore.

A native of the Netherlands, Vijay was educated at the University of Southampton, UK, and the University of Groningen, the Netherlands, holds a M.Sc. in Economics, and is also a CFA charter holder.



A/Prof Andrea KWA Lay Hoon 柯丽云

Deputy Director, Pharmacy (Research & Innovation), Singapore General Hospital; Associate Professor, Duke-NUS Medical School

新加坡中央医院药剂部研究与创新副处长; 杜克-新加坡国立大学医学院副教授

A/Prof Andrea Kwa Lay Hoon serves as Pharmacy Clinician Scientist and Deputy Director (Research & Innovation), Pharmacy, at Singapore General Hospital, and is a faculty member of the Emerging Infectious Diseases Programme at Duke-NUS Medical School. A distinguished pharmacist clinician-scientist, she specialises in critical care medicine, infectious diseases and antimicrobial resistance, with research spanning phage therapy, antibiotic combination testing, antimicrobial pharmacokinetics and pharmacodynamics, molecular diagnostics, epidemiology, and AI-enabled antimicrobial stewardship. Her translational research bridges scientific discovery and clinical practice to improve patient outcomes. A recipient of the National Day Awards Commendation Medal and NMRC Clinician Scientist Award, she has authored more than 140 publications.



A/Prof Joanne NGEOW 饶润仪

Associate Professor of Genomic Medicine, Lee Kong Chian School of Medicine, Nanyang Technological University; Head, Cancer Genetics Service, and Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore

南洋理工大学李光前医学院基因组医学副教授；
新加坡国立癌症中心癌症基因咨询服务主任、肿瘤内科高级顾问

A/Prof Joanne Ngeow is Associate Professor of Genomic Medicine at the Lee Kong Chian School of Medicine, Nanyang Technological University, and Senior Consultant in the Division of Medical Oncology at the National Cancer Centre Singapore (NCCS), where she currently heads the Cancer Genetics Service. A/Prof Ngeow was awarded consecutive fellowships to undertake a Cancer Genomic Medicine Fellowship at the Cleveland Clinic, Ohio (2010–2014), under the mentorship of Prof Charis Eng. Concurrently she completed a Master of Public Health at Johns Hopkins Bloomberg School of Public Health, majoring in Health Finance, making her one of few clinical cancer geneticists globally with formal training spanning bench research, clinical practice, and health economics. A/Prof Ngeow is a Principal Investigator of the Health for Life in Singapore (HELIOS) Study, Chair of the International Society for Hereditary Gastrointestinal Tumors (InSiGHT). She has published extensively in leading journals including Journal of Clinical Oncology, Annals of Oncology, and Human Molecular Genetics



Dr Kate QI 齐欢

Founder & CEO, SG Diagnostics

SG Diagnostics 创始人兼首席执行官

Dr. Kate Ql is the CEO and founder of sG Dlagnostics, a singapore-based company that initiallygained prominence during the COvID-19 pandemic as the only local brand to receive formalapproval from the Health Sciences Authority (HSA) for its antigen test kit. Under Dr. Kate's leader-ship. sG Diagnostics secured strategic investment and majority ownership from the U.S. -basedInnova Medical Group in 2021, allowing the company to have significant international expansion.

Today, SG Diagnostics' focus has broadened to encompass both chronic diseases and infectiousdiseases, providing a comprehensive range of diagnostic solutions. The company's chronicdisease products are widely distributed across Singapore and the Asia-Pacitic (APAC) region.
addressing critical health challenges.

Dr. Kate holds a PhD from Nanyang Technological University (NTu), Singapore, specializing innanomaterials and diagnostic technologies. During her postdoctoral research, she led a govern-ment-funded project worth over SGD 1.2 million, focusing on the development of diagnostic testreagents. In 2019, she was named one of the Hurun China Under 30s to Watch' and recelved the
Suzhou Talent award.



Dr Wei Yang CHEONG 张伟洋

Vice Provost for Strategic Research Partnerships in Singapore Management University; Senior Adviser for Health Economics at Singapore's Ministry of Health; Chair of the Board, Advanced Cell Therapy and Research Institute of Singapore (ACTRIS)

新加坡管理大学战略研究合作副教务长;新加坡卫生部卫生经济学高级顾问;新加坡细胞治疗与研究院董事会主席

As Vice Provost (Strategic Research Partnerships), Dr Cheong develops multi-disciplinary, strategic research partnerships with government and industry, to advance the international standing of SMU' s research.

Prior to SMU, as DS(Technology/MOH), he fought COVID-19, and developed the research and innovation ecosystem and data, IT and cybersecurity architectures to achieve population health, precision health and preventive health.

As DCEO(NRF), he implemented the S$19B RIE2020 plan and developed the S$25B RIE2025 plan. In MOE, he led educational policy, research, and international benchmarking. In MTI, he oversaw EDB and Economic Strategies Committee (chaired by President Tharman). In MOF, he shaped Singapore' s long-term fiscal sustainability.



Ti-Hwei HOW 侯志辉

Founder & Principal Advisor, The Impact Catalyst SG; Senior Advisor of ASK Health Asia

The Impact Catalyst SG 创始人兼首席顾问;ASK Health Asia 高级顾问

Ti-Hwei is Senior Advisor to ASK Health Asia, and Founder & Principal Advisor of The Impact Catalyst. His advisory work focuses on bringing together stakeholders across the healthcare ecosystem to drive innovation, improve access, and enable better outcomes.

Ti-Hwei has over 30 years of industry experience across AstraZeneca, Johnson & Johnson, and Procter & Gamble. He most recently served as Vice President, Oncology & Market Access for International Markets at AstraZeneca, covering Australia/ New Zealand, Asia, Eurasia, Middle East/ Africa, and Latin America. During his tenure, he helped scale AstraZeneca' s oncology business to become the number one oncology company in the region.

In addition to his corporate leadership experience, Ti-Hwei brings strong governance and industry ecosystem credentials. He is an Accredited Board Director with the Singapore Institute of Directors, a Member of the Singapore Pharmacy Council, and has served as President of the Singapore Association of Pharmaceutical Industries and Chair of the EuroCham Singapore Healthcare Committee.



Zhiping CHEN 陈治平

CEO, Shengsheng International Logistics

生生国际总裁

Mr. Zhiping Chen is currently CEO for Shengsheng International ("SSI"), a specialized supply chain company servicing the life science and biopharma industry globally. Under his leadership, SSI has successfully supported the development of many new drug and advanced therapies, from R&D to clinical stages and through commercialization in different markets.

Mr. Chen brings over 20 years of experience in international corporate finance and investments. Before taking on his current industry role, he co-founded RJ Capital Group, a boutique merchant bank specializing in the digital economy and cross-border investments. He previously served as Managing Director at The Blackstone Group' s Asia headquarters in Hong Kong and worked in the investment banking division of Deutsche Bank AG, where he led and participated in numerous corporate advisory and capital markets transactions across Asia.

Mr. Chen holds a Bachelor' s degree in Economics from the China Institute of Finance and Banking and a M.S. degree from Columbia University. He also completed his EMBA at the Cheung Kong Graduate School of Business and pursued executive training at IMD and Tel Aviv University.



A/Prof Henry HO Sun Sien 何升全

Executive Director, National Health Innovation Centre Singapore (NHIC); Deputy Chief Executive Officer, Discovery & Future Health, Singapore General Hospital

新加坡国家医疗创新中心执行总监;新加坡中央医院副行政总裁（探索与未来医疗）

A/Prof Henry Ho Sun Sien is the Deputy Chief Executive Officer (Discovery & Future Health) of Singapore General Hospital. His role is to transform healthcare by harnessing research, innovation and implementation of future health systems. He is immediate past chairman of surgery for SGH and National Cancer Center Singapore (2022-2026). He is also the Executive Director for National Healthcare Innovation Center (NHIC). It translates research and match technology to answer clinical needs towards commercial entity while ensuring clinical impact. He is a Urologist in SGH. He is one of the founding inventors of Mona Lisa (Biobot Surgicals Pte Ltd) that delivered accurate and safe biopsy in prostate cancer.



A/Prof Andrea LOW Hsiu Ling 刘秀玲

Research Director, Research Office; Senior Consultant, Department of Rheumatology & Immunology, Singapore General Hospital

新加坡中央医院研究处主任；风湿与免疫学高级顾问医生

A/Prof Low Hsiu Ling, Andrea is a Senior Consultant in Rheumatology and Immunology. Her primary research interest is systemic sclerosis and the connective tissue diseases. She leads a nationwide cohort on systemic sclerosis, as well as an international consortium across the Asia-Pacific region. As Research Director of Singapore General Hospital, she oversees the strategic research planning, stakeholder engagement across the institution, international research collaborations and research talent development.



Dr Xiaoming PENG 彭晓明

CEO, Lion TCR

来恩生物首席执行官

Dr Peng obtained his PhD degree from the National University of Singapore (NUS) and previously served as Adjunct Associate Professor at NUS. He has over 20 years of experience in strategic planning, R&D project management and technology commercialization in the technology sector, with extensive expertise spanning AI, biotechnology and healthcare. He previously worked at the Agency for Science, Technology and Research (A*STAR), where he held senior positions including Head of Division & Senior Scientist, and Deputy Director of Strategic Planning for China. He also has experience working with multinational corporations and startups. Currently serving as CEO of Lion TCR, Dr Peng is responsible for corporate strategy and fundraising, and has successfully completed multiple rounds of USD- and RMB-denominated financing.



A/Prof Adrian TEO 赵奇强

Scientific Co-Founder, BetaLife Pte Ltd

BetaLife 科学联合创始人

A/P Adrian TEO obtained his B.Sc. (1st Class) from the National University of Singapore (NUS). He completed his Ph.D. on stem cell biology with Prof Ludovic Vallier at the University of Cambridge, under an A*STAR Scholarship. Concurrently, he was also an Honorary Cambridge Commonwealth Trust Scholar. He then trained with Prof Rohit Kulkarni at Joslin Diabetes Center, Harvard Medical School, as a Juvenile Diabetes Research Foundation (JDRF) fellow, on pancreatic islet biology and diabetes. Adrian is currently a Senior Principal Investigator at the Institute of Molecular and Cell Biology (IMCB), A*STAR; Division Director of the Cellular Engineering and Therapy (CET) Division; Division Director of the Biomolecular Engineering and Technologies (BET) Division at IMCB, A*STAR; and a tenured Associate Professor at Yong Loo Lin School of Medicine, National University of Singapore. His laboratory uses human pluripotent stem cells for disease modelling of diabetes, developing therapeutics and cell therapy. He is also a co-founder of BetaLife Pte Ltd focused on the use of stem cell therapy for diabetes patients. He is a member of the Oxbridge Society of Singapore, the International Society for Stem Cell Research (ISSCR) and an EXCO member/Vice-Secretary of the Stem Cell Society Singapore (SCSS).



Bowen WEI 魏博文

Associate Director, International Business Development and Strategy, Innogen

银诺医药国际业务拓展和战略副总监

Mr. Bowen Wei is a biopharma strategy and business development professional operating at the intersection of science, capital, and global transactions. He serves as Associate Director of International Business Development at Innogen Pharmaceuticals (2591.HK), leading APAC business development. With academic and professional experience across China and Australia, he has built a strong track record in cross-border partnering, investment, M&A, and licensing. His transaction experience includes an M&A deal exceeding €100 million and an in-licensing transaction approaching RMB 1 billion in total potential value. Bowen works with pharmaceutical and biotechnology companies globally to connect differentiated science with capital and strategic partners.

ASK HEALTH ASIA PRIVATE LIMITED

Singapore | 10 Central Exchange Green Pixel

Shanghai | 507,5F Ascendas Plaza,333 Tian Yao Qiao Road,Xuhui District

Beijing | 118,L3,28 Guandongdian Rd

Macau | No.517 Nanwan Avenue, 19th Floor, Nantong Commercial Building,Macau

+86 21 65053288

www.askhealthasia.com

contact@askhealth.com.cn

https://cn.linkedin.com/company/askhealth

